Department of Plastic and Aesthetic Surgery and Burns, Second Xiangya Hospital, Central South University, Changsha, China.
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Aesthetic Plast Surg. 2021 Oct;45(5):2350-2362. doi: 10.1007/s00266-021-02196-5. Epub 2021 Mar 5.
Scars exposed on the body surface lead to a large psychological burden on patients. However, no satisfactory scar treatments exist. Botulinum toxin type A is a neurotoxin that has been widely applied in the plastic and cosmetic surgery field. The purpose of this meta-analysis was to assess the efficacy and safety of botulinum toxin in scar management.
PubMed, the Cochrane Library, EMBASE, MEDLINE, and Web of Science were searched for randomized controlled trials that evaluated the efficacy of botulinum toxin injections in preventing postoperative scars and improving scars quality and were published prior to Dec. 29, 2020. The outcome indicators were the visual analog scale score, Vancouver scar scale score, Stony Brook scar evaluation scales score, scar width, patient self-assessment results, and complications.
Seventeen randomized controlled trials with a total of 633 cases were identified in this meta-analysis. The quantitative synthesis results showed that compared with the control group, the botulinum toxin group had a significantly lower VSS score (MD = -0.97, 95%CI = -1.56 to -0.39, p = 0.001), higher VAS score (MD = 1.26, 95%CI = 1.04 to 1.47, p < 0.00001), thinner scar width (MD = -0.25, 95%CI = -0.37 to -0.12, p < 0.0001) and higher patient satisfaction (RR = 3.38 95%CI = 1.45 to 7.89, p = 0.005). There were no significant differences between the two groups in the number of adverse events.
This meta-analysis demonstrated that botulinum toxin injections can significantly improve cosmetic appearance and postoperative scar quality. At the therapeutic dose, no significant complications were observed, indicating that botulinum toxin injections are safe.
This journal requires that authors assign a level of evidence to each article. For a full description of these evidence-based medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
体表瘢痕会给患者带来较大的心理负担。但目前尚无令人满意的瘢痕治疗方法。肉毒毒素 A 型是一种神经毒素,已广泛应用于整形美容外科领域。本荟萃分析旨在评估肉毒毒素在瘢痕管理中的疗效和安全性。
检索了 PubMed、Cochrane 图书馆、EMBASE、MEDLINE 和 Web of Science 中截至 2020 年 12 月 29 日评估肉毒毒素注射预防术后瘢痕及改善瘢痕质量的疗效的随机对照试验,纳入研究对象为接受手术治疗的患者。结局指标包括视觉模拟评分(VAS)、温哥华瘢痕量表(VSS)评分、Stony Brook 瘢痕评估量表(SBS)评分、瘢痕宽度、患者自评结果和并发症。
本荟萃分析共纳入 17 项随机对照试验,共计 633 例患者。定量合成结果显示,与对照组相比,肉毒毒素组 VSS 评分较低(MD=-0.97,95%CI=-1.56 至-0.39,p=0.001),VAS 评分较高(MD=1.26,95%CI=1.04 至 1.47,p<0.00001),瘢痕宽度较窄(MD=-0.25,95%CI=-0.37 至-0.12,p<0.0001),患者满意度较高(RR=3.38,95%CI=1.45 至 7.89,p=0.005)。两组不良反应发生率无显著差异。
本荟萃分析表明,肉毒毒素注射可显著改善美容外观和术后瘢痕质量。在治疗剂量下,未见明显并发症,表明肉毒毒素注射是安全的。
证据水平 III:本刊要求作者为每篇文章分配证据水平。如需详细了解这些循证医学分级,请参考目录或在线作者指南(www.springer.com/00266)。